Health Canada is informing Canadians that Novo Nordisk Canada Inc. has agreed to voluntarily recall two lots (YW60335 and YW60351) of their product, GlucaGen Hypokit (DIN 02333627) currently available on the Canadian market. Novo Nordisk Canada Inc. is requesting that wholesalers, pharmacies and hospitals immediately stop sale and recall...

Novo Nordisk announced today the availability of NovoDoseTM – the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo...

The continuing controversy surrounding the cardiovascular risk of GlaxoSmithKline’s diabetes drug Avandia has led to sharp declines in its use and a surge in sales of the competing drug, Actos. Although the drugs are similar and both had FDA warnings in 2007, Takeda’s Actos has been perceived to be safer for the treatment...

GlaxoSmithKline confirmed today that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA  review of recommendations from its  Advisory Committee meeting July 13-14. Patients already...

GlaxoSmithKline confirmed that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow the diabetes drug Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions (20)...

Avandia Safety Questioned:  The New York Times reports that diabetes drug maker SmithKline did not reveal the results of a study showing its drug Avandia was riskier to the heart than a competing drug, Actos. The New York Times states, “instead of publishing the results, the company spent the next 11 years trying to cover them...

The diabetes drug, Avandia, may be more dangerous than was previously reported.  According to CNN,  a review of Avandia released last week by the FDA states that officials overseeing GlaxoSmithKline Plc’s RECORD study repeatedly submitted sloppy data and failed to follow up on reports of problems in patients — including reports...

Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when...

A press release issued today by Depomed, Inc. and Santarus, Inc says that according to the clinical trial results, patients previously intolerant of metformin may be able to tolerate higher efficacious doses of metformin when treated with GLUMETZA, with fewer gastrointestinal side effects. GLUMETZA is a once-daily, extended release...

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from a study comparing the effect of long-term treatment with either Byetta (exenatide) injection or Lantus(R) (insulin glargine) on overall beta-cell function. Three years of Byetta therapy improved indices of beta-cell function assessed four weeks after discontinuing...